Hostname: page-component-8448b6f56d-sxzjt Total loading time: 0 Render date: 2024-04-24T20:29:17.170Z Has data issue: false hasContentIssue false
  • English
  • Français

An Outbreak of Pertussis in a Hematology-Oncology Care Unit: Implications for Adult Vaccination Policy

Published online by Cambridge University Press:  21 June 2016

Brian R. Boulay ,
Carolyn J. Murray ,
Judy Ptak ,
Kathryn B. Kirkland ,
Jose Montero  and
Elizabeth A. Talbot
Brian R. Boulay*
Affiliation:
Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon
Carolyn J. Murray
Affiliation:
Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon
Judy Ptak
Affiliation:
Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon
Kathryn B. Kirkland
Affiliation:
Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon
Jose Montero
Affiliation:
Department of Health and Human Services, Concord, New Hampshire
Elizabeth A. Talbot
Affiliation:
Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon Department of Health and Human Services, Concord, New Hampshire
*
Section of General Internal Medicine, Dartmouth Hitchcock Medical Center, One Medical Center Drive, LebanonNH 03756 (, Brian.R.Boulay@hitchcock.org)
Get access Rights & Permissions [Opens in a new window]

Abstract

A pertussis outbreak in a hematology-oncology care unit involved 10 (8.5%) of 117 employees. The source was an employee who contracted pertussis via a family contact. No screened patients contracted pertussis, likely because of isolation measures. Hospitals should consider employee immunization with acellular vaccine in healthcare settings where pertussis has high rates of morbidity and mortality.

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 27 , Issue 1 , January 2006 , pp. 92 - 95
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Jenkinson, D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed) 1988; 296:612–614.CrossRefGoogle ScholarPubMed
2.Centers for Disease Control and Prevention. Pertussis outbreak—Vermont, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:822–826.Google Scholar
3.Gehanno, JF, Pestel-Caron, M, Nouvellon, M, Caillard, JF. Nosocomial pertussis in healthcare workers from a pediatric emergency unit in France. Infect Control Hosp Epidemiol 1999; 20:549–552.CrossRefGoogle ScholarPubMed
4.Bassinet, L, Matrat, M, Njamkepo, E, Aberrane, S, Housset, B, Guiso, N. Nosocomial pertussis outbreak among adult patients and healthcare workers. Infect Control Hosp Epidemiol 2004; 25:995–997.Google Scholar
5.Linnemann, CC Jr, Ramundo, N, Perlstein, PH, Minton, SD, Englender, GS. Use of pertussis vaccine in an epidemic involving hospital staff. Lancet 1975; 2:540–543.CrossRefGoogle Scholar
6.Center for Disease Control and Prevention. Pertussis—United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002;51:73–76.Google Scholar
7.Council of State and Territorial Epidemiologists (CSTE). 1997 Position statements: position statement 9. Paper presented at: CSTE National Meeting; June 16-19, 1997; Saratoga Springs, NY.Google Scholar
8.Sutter, RW, Cochi, SL. Pertussis hospitalization and mortality in the United States, 1985-1988. JAMA 1992; 267:386–391.CrossRefGoogle ScholarPubMed
9.Senzilet, LD, Halperin, SA, Spika, JS, Alagaratnam, M, Morris, A, Smith, B. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Sentinel Health Unit Surveillance System Pertussis Working Group. Clin Infect Dis 2001; 32:1691–1697.Google Scholar
10.Lee, LH, Pichichero, ME. Cost of illness due to Bordetella pertussis in families. Arch Earn Med 2000; 9:989–996.Google ScholarPubMed
11.Chapman, TM, Goa, KL. Reduced-antigen combined diphtheria-tetanus-acellular pertussis vaccine (Boostrix). Drugs 2003; 63:1407–1413.Google Scholar
12.Halperin, SA, Smith, B, Russell, M, et al. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine 2000; 18:1312–1319.Google Scholar
13.Bartels, I, Jungert, J, Lugauer, S, Stehr, K, Heininger, U. Immunogenicity and reactogenicity of a single dose of a diphtheria-tetanus-acellular pertussis component vaccine (DTaP) compared to a diphtheria-tetanus toxoid (Td) and a diphtheria toxoid vaccine (d) in adults. Vaccine 2001; 19:3137–3145.Google Scholar
14.Campins-Marti, M, Cheng, HK, Forsyth, K, et al. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. International Consensus Group on Pertussis Immunisation. Vaccine 2001; 20:641–646.CrossRefGoogle ScholarPubMed
15.National Advisory Committee on Immunization. Prevention of pertussis in adolescents and adults. Can Commun Dis Rep 2003; 29:1–9.Google Scholar
16.Hoppe, JE. State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis. Infection 1998; 26:242–246.Google Scholar